Expert Practice On-Demand Presentations

Renal cell carcinoma: The emerging role of adjuvant and neoadjuvant therapy
Discussant: Alastair W. S. Ritchie, MD

A 63-year-old man presented with left flank pain, night sweats, and weight loss of 7 kg.

CT: 11.5-cm left renal mass. No hepatic or pulmonary metastases
Labs: Hgb 11.0 g/dL, calcium, LDH, and creatinine are normal
Surgery: Left radical nephrectomy
Pathology: Fuhrman grade 3 clear cell carcinoma with moderate tumor necrosis invading the left renal vein. Metastatic carcinoma in 1 perinephric lymph node (pT3N1M0).

PART 1

Which of the following best approximates this patient’s 5-year survival with surgery alone?(polling)

PART 2

Which of the following would you recommend postoperatively for this patient?(survey)

PART 3

If you had been consulted preoperatively regarding this patient’s management, which would you have recommended?(online surveys)

Renal cell carcinoma: The emerging role of adjuvant and neoadjuvant therapy

Alastair W. S. Ritchie, MD
Medical Research Council
London, United Kingdom

Intermediate-risk renal cell carcinoma: Best choice and sequencing of therapy

Camillo Porta, MD
IRCCS San Matteo University Hospital
Pavia, Italy

PSA-only relapse following local therapy for high-risk prostate cancer

Kurt Miller, MD
Benjamin Franklin Medical Center
Berlin, Germany

Hormone-responsive prostate cancer with bone metastases: How should therapy be sequenced?

Peter Mulders, MD, PhD
University Medical Center Nijmegen
Nijmegen, The Netherlands

Castration-resistant prostate cancer: Optimal management of a patient with good performance status

Camillo Porta, MD
IRCCS San Matteo University Hospital
Pavia, Italy